0. DOCID:31345 SCORE: 0.00493894905082033
DOCNO: 16392666
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: analogs & derivatives
QUALIFIER: chemistry
AUTHOR: Rui Liu R
AUTHOR: Cheng-Bin Cui CB
AUTHOR: Lin Duan L
AUTHOR: Qian-Qun Gu QQ
AUTHOR: Wei-Ming Zhu WM
AFFILIATION: Key Laboratory of Marine Drugs, Chinese Ministry of Education, PR China.
PUBTYPE: Journal Article
JOURNALTITLE: Archives of pharmacal research.
COUNTRY: Korea (South)
TITLE: Potent in vitro anticancer activity of metacycloprodigiosin and undecylprodigiosin from a sponge-derived actinomycete Saccharopolyspora sp. nov.
PUBDATE: 20051201
Bioassay-guided fractionation of CHCl3 extract from the fermentation broth of a sponge Mycale plumose-derived actinomycete Saccharopolyspora sp. nov., led to the isolation of two known prodigiosin analogs--metacycloprodigiosin (1) and undecylprodigiosin (2). These compounds exhibited significant cytotoxic activities against five cancer cell lines: P388, HL60, A-549, BEL-7402, and SPCA4. This is the first report on the significant cytotoxicity of metacycloprodigiosin (1) against human cancer cell lines.

1. DOCID:31156 SCORE: 0.00493725395208573
DOCNO: 16274621
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: Ke Qiang Chen KQ
AUTHOR: Pablo Iribarren P
AUTHOR: Wang Hua Gong WH
AUTHOR: Ji Ming Wang JM
AFFILIATION: School of Agriculture and Biology, Shanghai Jiaotong University, Shanghai 201101, China.
PUBTYPE: Journal Article
JOURNALTITLE: Cellular & molecular immunology.
COUNTRY: China
TITLE: The Essential Role of Phosphoinositide 3-Kinases (PI3Ks) in Regulating Pro-Inflammatory Responses and the Progression of Cancer.
PUBDATE: 20050801
Phosphoinositide 3-Kinases (PI3Ks) are proteins coupled to a variety of cell surface receptors and play a key role in signal transduction cascade regulating fundamental cellular functions such as transcription, proliferation, and survival. PI3Ks also are important in disease processes such as inflammation and cancer. The aim of this review is to outline current understandings of the PI3K family, mechanism of their activation, their role in inflammatory responses and the development of malignant tumors.

2. DOCID:29862 SCORE: 0.00308287117017039
DOCNO: 15935730
OWNER: NLM
STATUS: In-Process
AUTHOR: Beatriz M Carreno BM
AUTHOR: Laura L Carter LL
AUTHOR: Mary Collins M
AFFILIATION: Inflammation, Wyeth Research, 200 CambridgePark Drive, Cambridge, Massachusetts 02140, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Current opinion in pharmacology.
COUNTRY: England
TITLE: Therapeutic opportunities in the B7/CD28 family of ligands and receptors.
PUBDATE: 20050801
The CD28 and B7 protein families are critical regulators of immune responses and, in the past few years, several new family members have been identified. Preclinical studies exploring the role of members of the CD28 and B7 families support the targeting of these pathways for new therapeutic approaches. Indeed, recent Phase I clinical studies using agonists and antagonists of the CD28/CTLA-4/B7 pathway have shown promise in inflammatory diseases and cancer.

3. DOCID:31024 SCORE: 0.00308285665676592
DOCNO: 16474786
OWNER: NLM
STATUS: In-Process
AUTHOR: Fiona C Burkhard FC
AUTHOR: Martin Schumacher M
AUTHOR: Urs E Studer UE
AFFILIATION: Department of Urology at the University Hospital in Bern, Switzerland.
PUBTYPE: Journal Article
JOURNALTITLE: Nature clinical practice. Urology.
COUNTRY: United States
TITLE: The role of lymphadenectomy in prostate cancer.
PUBDATE: 20050701
It has been shown that an adequate lymphadenectomy for exact staging of prostate cancer consists of removal of all the tissue along the external iliac vein, in the obturator fossa and along the internal iliac artery. Morbidity associated with this procedure is low, if certain technical details are respected. This review discusses in detail the indications for lymphadenectomy and the extent of dissection, based on the localization of the positive nodes. The potential therapeutic impact of extended lymph node dissection in men with prostate cancer is also addressed.

4. DOCID:31187 SCORE: 0.0030793491137463
DOCNO: 15071997
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Adenocarcinoma
DESCRIPTOR: Rectal Neoplasms
QUALIFIER: therapeutic use
QUALIFIER: methods
AUTHOR: S V Peliukhovs'kyĭ SV
AUTHOR: A V Chornobaĭ AV
PUBTYPE: Journal Article
JOURNALTITLE: Klinichna khirurhiia / Ministerstvo okhorony zdorov'ia Ukraïny, Naukove tovarystvo khirurhiv Ukraïny.
COUNTRY: Ukraine
TITLE: [Experience of surgical treatment of rectal cancer with chemoradiation component on the first stage]
PUBDATE: 20040101
Experience of treatment of 14 patients with cancer recti, using chemoradiation impact on the tumor--endolymphatic polychemotherapy according to MFP (metotrexat, fluorouracyl cysplatin) schema and intense irradiation (summary focal dose 25 Gr) on the first stage with subsequent performance of surgical intervention in terms before 24 hours after completion of irradiation. The immediate results of treatment are estimated. There was not revealed the postoperative complications frequency enhancement. The anal sphincter function restoration was observed at the same terms as after performance of conventional surgical treatment.

5. DOCID:30308 SCORE: 0.00295199962703133
DOCNO: 12044009
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Molecular Biology
QUALIFIER: metabolism
AUTHOR: William C Hahn WC
AUTHOR: Robert A Weinberg RA
AFFILIATION: Whitehead Institute for Biomedical Research, Massachusetts 02142, USA. William_Hahn@dfci.harvard.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nature reviews. Cancer.
COUNTRY: England
TITLE: Modelling the molecular circuitry of cancer.
PUBDATE: 20020501
Cancer arises from a stepwise accumulation of genetic changes that liberates neoplastic cells from the homeostatic mechanisms that govern normal cell proliferation. In humans, at least four to six mutations are required to reach this state, but fewer seem to be required in mice. By rationalizing the shared and unique elements of human and mouse models of cancer, we should be able to identify the molecular circuits that function differently in humans and mice, and use this knowledge to improve existing models of cancer.

6. DOCID:30007 SCORE: 0.00254541640568559
DOCNO: 12542402
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: diagnosis
QUALIFIER: therapy
AUTHOR: M Cristofanilli M
AUTHOR: G N Hortobagyi GN
AFFILIATION: Department of Breast Medical Oncology, The University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 424, Houston, Texas 77030, USA. mcristof@notes.mdacc.tmc.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Endocrine-related cancer.
COUNTRY: England
TITLE: Molecular targets in breast cancer: current status and future directions.
PUBDATE: 20021201
Our increasing understanding of the pathophysiologic mechanisms of breast carcinogenesis has generated detailed information about the potential roles of specific biomolecular markers in this process. Furthermore, in the last few years the process of targeted drug design has become faster and more sophisticated, providing a variety of agents targeted at these molecules. In this review, we describe the most widely recognized molecular targets in breast cancer.

7. DOCID:31986 SCORE: 0.00231932462891969
DOCNO: 16357125
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: Peter A Jones PA
AUTHOR: Robert Martienssen R
AFFILIATION: University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, California and Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
PUBTYPE: Journal Article
JOURNALTITLE: Cancer research.
COUNTRY: United States
TITLE: A Blueprint for a Human Epigenome Project: The AACR Human Epigenome Workshop.
PUBDATE: 20051201
Epigenetic processes control the packaging and function of the human genome and contribute to normal and pathologic states, including cancer. The time is ripe to undertake an international effort to identify all the chemical changes and relationships between chromatin constituents that provide function to the genetic code. A timely workshop of leading experts, convened by the American Association for Cancer Research (AACR), confirmed that the technology is at hand to begin defining human epigenomes at high resolution. (Cancer Res 2005; 65(24): 11241-6).

8. DOCID:31244 SCORE: 0.00231929812935477
DOCNO: 16297338
OWNER: NLM
STATUS: In-Data-Review
AUTHOR: Robert Wai-Sui Lim RW
AUTHOR: Jin-Mei Wu JM
AFFILIATION: Department of Medical Pharmacology and Physiology, University of Missouri-Columbia, Columbia, Missouri, 65212 USA. limr@health.missouri.edu.
PUBTYPE: Journal Article
JOURNALTITLE: Acta pharmacologica Sinica.
COUNTRY: China
TITLE: Molecular mechanisms regulating expression and function of transcription regulator inhibitor of differentiation 3.
PUBDATE: 20051201
The transcription factor antagonist inhibitor of differentiation 3 (Id3) has been implicated in many diverse developmental, physiological and pathophysiological processes. Its expression and function is subjected to many levels of complex regulation. This review summarizes the current understanding of these mechanisms and describes how they might be related to the diverse functions that have been attributed to the Id3 protein. Detailed understanding of these mechanisms should provide insights towards the development of therapeutic approaches to various diseases, including cancer and atherogenesis.

9. DOCID:29669 SCORE: 0.00216757096265898
DOCNO: 16163438
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Attitude to Death
DESCRIPTOR: Bioethical Issues
DESCRIPTOR: Esophageal Neoplasms
DESCRIPTOR: Trust
QUALIFIER: ethics
AUTHOR: Jaime Duclos J
AFFILIATION: Servicio de Medicina, Hospital Naval Almirante Nef, Viña del Mar, Chile. jduclos@vtr.net
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: Revista médica de Chile.
COUNTRY: Chile
TITLE: [Death as a moment of peace and trust]
PUBDATE: 20050801
A young woman with aphagia, probably caused by an esophageal cancer that could not be confirmed, is reported. Fully respecting the will of the patient at the end of her life, palliative care measures were instituted, even though the diagnosis was uncertain. This case emphasizes the integrative role of internists and the difficulty of making decisions about life and death without being in close touch with desires of our patients.

10. DOCID:30111 SCORE: 0.00216756906099651
DOCNO: 14678185
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Kidney Pelvis
QUALIFIER: secondary
QUALIFIER: secondary
QUALIFIER: pathology
AUTHOR: Takashi Kobayashi T
AUTHOR: Keiji Ogura K
AUTHOR: Koji Nishizawa K
AUTHOR: Makoto Ono M
AUTHOR: Yasushi Ueno Y
AUTHOR: Hidenori Miyake H
AUTHOR: Yoshihiro Ide Y
AFFILIATION: Departments of Urology, Neurosurgery and Surgical Pathology, Hamamatsu Rosai Hospital, Hamamatsu, Japan. salecao@remus.dti.ne.jp
PUBTYPE: Case Reports
PUBTYPE: Journal Article
JOURNALTITLE: International journal of urology : official journal of the Japanese Urological Association.
COUNTRY: Australia
TITLE: Clinically isolated cerebellar metastasis of renal pelvic urothelial cancer.
PUBDATE: 20040101
A 70-year-old man who had undergone radical surgery for renal pelvic transitional cell carcinoma 9 months previously developed solitary cerebellar metastasis. Despite neurosurgical removal, the patient died and post-mortem pathological examination revealed microscopic metastatic lesions within microvessels of the lung. No other lesion, including local residual cancer, was detected.

11. DOCID:31766 SCORE: 0.00214328857031877
DOCNO: 15685832
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: drug therapy
QUALIFIER: antagonists & inhibitors
AUTHOR: Jeffrey A Meyerhardt JA
AUTHOR: Charles S Fuchs CS
AFFILIATION: Dana-Farber Cancer Institute, Brigham and Women's Hospital Boston, Massachusetts 02115, USA. jmeyerhardt@partners.org
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Oncology (Williston Park, N.Y.)
COUNTRY: United States
TITLE: Epidermal growth factor receptor inhibitors and colorectal cancer.
PUBDATE: 20041201
The epidermal growth factor receptor (EGFR) plays an important role in cell growth, differentiation, and survival. Targeting EGFR in patients with colorectal cancer has become an important therapeutic tool. Recently, a monoclonal antibody against the extracellular domain of the receptor (cetuximab [Erbitux]) has been approved for the treatment of patients with EGFR-positive metastatic disease refractory to irinotecan (Camptosar)-based therapy. The role of other targeted agents against EGFR, including other monoclonal antibodies as well as inhibitors of the intracellular tyrosine kinase domain, will also be discussed.

12. DOCID:31178 SCORE: 0.00209213331052968
DOCNO: 15645019
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Drug Design
QUALIFIER: methods
AUTHOR: Sheila A Doggrell SA
AFFILIATION: University of Queensland, School of Biomedical Sciences, QLD 4072, Australia. s_doggrell@yahoo.com
PUBTYPE: Congresses
JOURNALTITLE: Drug news & perspectives.
COUNTRY: Spain
TITLE: New drugs and new targets.
PUBDATE: 20041101
At the 8th World Congress on Clinical Pharmacology and Therapeutics, held August 1-6, 2004, in Queensland, Australia, there were late-breaking news symposia on presynaptic receptors as targets in the treatment of schizophrenia; cyclooxygenase inhibition, present and future; adiposity, drug treatment and causes; G-protein-coupled receptors, important new targets; osteoporosis, causes, prevention and cures; ischemic stroke; drugs and arrhythmias, causes and cures; and the pharmacology of cardiac protection. One of the plenary lectures was of targeted cancer therapies. The new drugs and new targets for therapeutic intervention from these presentations are discussed in this report.

13. DOCID:31249 SCORE: 0.00204789593241019
DOCNO: 16195753
OWNER: NLM
STATUS: MEDLINE
DESCRIPTOR: Internet
DESCRIPTOR: Mass Media
QUALIFIER: prevention & control
AUTHOR: K Viswanath K
AFFILIATION: Department of Society, Human Development and Health, Harvard School of Public Health, Boston, Massachusetts 02115, USA. vish_viswanath@dfci.harvard.edu
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Nature reviews. Cancer.
COUNTRY: England
TITLE: Science and society: the communications revolution and cancer control.
PUBDATE: 20051001
Advances in communications technology, particularly with regards to computer-based media, have opened up exciting possibilities to intervene and influence the trajectory of cancer control, from disease prevention to survivorship, and to reduce the cancer burden. The resulting explosion in cancer information in the mass media and on the Internet, however, also offers challenges in terms of equality in access to information and the ability to act on it, as well as in making sure that it is accurate, readily available and easy to use.

14. DOCID:29521 SCORE: 0.00191826599643912
DOCNO: 15270644
OWNER: NLM
STATUS: MEDLINE
QUALIFIER: therapeutic use
QUALIFIER: immunology
QUALIFIER: therapy
QUALIFIER: therapeutic use
AUTHOR: Benjamin Levy B
AUTHOR: Dennis Panicalli D
AUTHOR: John Marshall J
AFFILIATION: Lombardi Comprehensive Cancer Center, 3800 Reservoir Rd NW, Washington, DC 20007, USA.
PUBTYPE: Journal Article
PUBTYPE: Review
JOURNALTITLE: Expert review of vaccines.
COUNTRY: England
TITLE: TRICOM: enhanced vaccines as anticancer therapy.
PUBDATE: 20040801
Renewed interest in immune therapies for the treatment of cancer has sparked a number of different immune stimulation approaches. These include antibody based, dendritic cell-based and vaccine-based therapies. The poxvirus-based vaccines incorporating a TRIad of COstimulatory Molecules (TRICOM) will be reviewed here. Through stimulation of cancer-specific T-cell responses, researchers have demonstrated interesting clinical efficacy in addition to the high safety profile in clinical trials.